Daewoong's IPF Treatment Granted Orphan Status in U.S. - (BusinessKorea via NewsPoints Desk)

  • Daewoong Pharmaceutical announced that it received an FDA orphan drug designation for its experimental drug DWN12088 to treat patients with idiopathic pulmonary fibrosis, reported BusinessKorea.

  • According to the news source, DWN12088 is an oral therapy with a mechanism that selectively inhibits prolyl-tRNA synthetase protein activity and excessive production of collagen. 

  • Preclinical study findings have demonstrated the efficacy and safety of the treatment compared to existing drugs, the news source added.

  • Daewoong has also submitted an application for a Phase I clinical trial to the Human Research Ethics Committee in Australia.

To read more NewsPoints articles, click here.

Reference Articles